SORRENTO THERAPEUTICS INC (SRNE) Forecast, Price Target & Analyst Ratings
NASDAQ:SRNE • US83587F2020
0.3073 USD
-0.08 (-20.26%)
At close: Feb 22, 2023
0.2801 USD
-0.03 (-8.85%)
After Hours: 2/22/2023, 8:27:19 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SORRENTO THERAPEUTICS INC (SRNE).
Forecast Snapshot
Consensus Price Target
$7.82
+ 2,444.76% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ4 / 2022
EPS Estimate-$0.23
Revenue Estimate16.905M
ChartMill Buy Consensus
82.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.82
Upside
+ 2,444.76%
From current price of $0.31 to mean target of $7.82, Based on 9 analyst forecasts
Low
$5.05
Median
$5.10
High
$13.65
Price Target Revisions
1 Month
-36.11%
3 Months
-36.11%
Price Target Summary
9 analysts have analysed SRNE and the average price target is 7.82 USD. This implies a price increase of 2444.75% is expected in the next year compared to the current price of 0.3073.
The average price target has been revised downward by 36.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
SRNE was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about SRNE.
In the previous month the buy percentage consensus was at a similar level.
SRNE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-02 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-08-09 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ4 / 2022
EPS Estimate-$0.23
Revenue Estimate16.905M
Revenue Q2Q29.28%
EPS Q2Q50.09%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
21.31%
EPS (1 Month)
0.00%
EPS (3 Months)
6.12%
Next Earnings Summary
The next earnings revenue estimate has been revised upward by 21.31% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.4M 48.11% | 40M 27.39% | 52.904M 32.26% | 58.222M 10.05% | 53.272M -8.50% | 207.44M 289.40% | |
| EBITDA YoY % growth | -248.41M -75.74% | -233.59M 5.97% | -388.989M -66.53% | N/A | N/A | N/A | |
| EBIT YoY % growth | -259.4M -72.47% | -244.6M 5.71% | -401.451M -64.13% | -404.9M -0.86% | -394.552M 2.56% | -238.206M 39.63% | |
| Operating Margin | -826.11% | -611.50% | -758.83% | -695.44% | -740.64% | -114.83% | |
| EPS YoY % growth | -2.25 -52.03% | -1.19 47.11% | -1.43 -20.17% | -1.20 15.83% | -0.90 25.00% | -0.53 41.81% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 22 | |
|---|---|
| EPS Q2Q % growth | -0.23 50.09% |
| Revenue Q2Q % growth | 16.905M 29.28% |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -97.046M 15.32% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.75%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
54.67%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
SORRENTO THERAPEUTICS INC / SRNE Forecast FAQ
What is the average price target for SORRENTO THERAPEUTICS INC (SRNE) stock?
9 analysts have analysed SRNE and the average price target is 7.82 USD. This implies a price increase of 2444.75% is expected in the next year compared to the current price of 0.3073.
Can you provide the consensus estimates for SORRENTO THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of SORRENTO THERAPEUTICS INC (SRNE) is -0.23 USD and the consensus revenue estimate is 16.91M USD.
What is the expected long term growth rate for SRNE stock?
The expected long term growth rate for SORRENTO THERAPEUTICS INC (SRNE) is 54.67%.